Gabapentin Tablet Dosing Recommendations
For neuropathic pain in adults, start gabapentin at 300 mg on day 1, increase to 600 mg/day (300 mg twice daily) on day 2, then 900 mg/day (300 mg three times daily) on day 3, with a target maintenance dose of 1800 mg/day (600 mg three times daily) for optimal efficacy. 1
Neuropathic Pain Dosing (Postherpetic Neuralgia, Diabetic Neuropathy)
The FDA-approved titration schedule is straightforward and evidence-based 1:
- Day 1: 300 mg once daily
- Day 2: 600 mg/day (300 mg twice daily)
- Day 3: 900 mg/day (300 mg three times daily)
- Target dose: 1800 mg/day (600 mg three times daily)
- Maximum dose: 3600 mg/day if needed, though additional benefit above 1800 mg/day is not consistently demonstrated 1
Key principle: Efficacy is demonstrated across 1800-3600 mg/day, but 1800 mg/day represents the optimal balance of efficacy and tolerability 1, 2. The maximum interval between doses should not exceed 12 hours 1.
Guidelines support this approach, recommending starting at 100-300 mg at bedtime or three times daily, with increases of 100-300 mg every 1-7 days as tolerated, requiring 3-8 weeks for full titration plus 2 weeks at maximum dose for adequate trial 3. However, the FDA label provides more specific and practical guidance for clinical use.
Epilepsy Dosing (Partial Onset Seizures)
Adults and Children ≥12 years:
- Starting dose: 300 mg three times daily
- Maintenance dose: 300-600 mg three times daily
- Maximum tested: 2400 mg/day (well tolerated long-term); 3600 mg/day used short-term in some patients 1
Pediatric Patients (3-11 years):
- Starting dose: 10-15 mg/kg/day in three divided doses
- Maintenance dose (ages 3-4): 40 mg/kg/day in three divided doses
- Maintenance dose (ages 5-11): 25-35 mg/kg/day in three divided doses
- Titrate upward over approximately 3 days 1
Renal Impairment Adjustments
Critical caveat: Gabapentin is renally eliminated; dose reduction is mandatory in renal impairment 1. Use the following table for patients ≥12 years:
- CrCl ≥60 mL/min: 900-3600 mg/day (300-1200 mg three times daily)
- CrCl 30-59 mL/min: 400-1400 mg/day (200-700 mg twice daily)
- CrCl 15-29 mL/min: 200-700 mg/day (200-700 mg once daily)
- CrCl <15 mL/min: 100-300 mg/day (100-300 mg once daily)
- Hemodialysis: Maintenance dose based on CrCl + supplemental dose of 125-350 mg after each 4-hour dialysis session 1
Elderly Patients
Dose selection requires extra caution due to age-related decline in renal function 1. Calculate creatinine clearance using Cockcroft-Gault equation and adjust accordingly. Guidelines specifically recommend lower starting doses and slower titration in geriatric patients 3, 4.
Discontinuation
Never stop abruptly. Taper gradually over minimum 1 week (longer at prescriber's discretion) to avoid withdrawal or seizure risk 1.
Common Pitfalls to Avoid
- Inadequate trial duration: Gabapentin requires 2 months or more for adequate assessment at maximum tolerated dose 3. Don't abandon therapy prematurely.
- Ignoring renal function: Failure to adjust for renal impairment leads to toxicity and adverse effects 1.
- Underdosing: Many patients receive subtherapeutic doses. Research shows Pakistani patients responded to lower doses (mean 470 mg/day) 5, but Western populations typically require 1800-3600 mg/day for neuropathic pain 2.
- Divided tablet misuse: If dividing scored 600 mg or 800 mg tablets, use the unused half within 28 days or discard 1.
Tolerability Considerations
Adverse effects (dizziness, drowsiness, somnolence) are typically mild-to-moderate and often subside within 10 days of initiation 2. These effects are dose-related and more common with rapid titration or polypharmacy, particularly with psychotropic medications 6. The gastroretentive formulation (Gralise®) offers once-daily dosing with improved tolerability but is only approved for postherpetic neuralgia 7.